HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease.

MLA

Zolotarev, Yurii A., et al. “HLDF-6 Peptides Exhibit Neuroprotective Effects in the Experimental Model of Preclinical Parkinson’s Disease.” Neuropeptides, vol. 96, Dec. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.npep.2022.102287.

APA

Zolotarev, Y. A., Shram, S. I., Dadayan, A. K., Dolotov, O. V., Markov, D. D., Nagaev, I. Y., Kudrin, V. S., Narkevich, V. B., Sokolov, O. Y., & Kost, N. V. (2022). HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson’s disease. Neuropeptides, 96, N.PAG. https://doi.org/10.1016/j.npep.2022.102287

Chicago

Zolotarev, Yurii A., Stanislav I. Shram, Aleksandr K. Dadayan, Oleg V. Dolotov, Dmitriy D. Markov, Igor Yu. Nagaev, Vladimir S. Kudrin, Viktor B. Narkevich, Oleg Yu. Sokolov, and Natalya V. Kost. 2022. “HLDF-6 Peptides Exhibit Neuroprotective Effects in the Experimental Model of Preclinical Parkinson’s Disease.” Neuropeptides 96 (December): N.PAG. doi:10.1016/j.npep.2022.102287.